-

08:30:46 AM

CVAC Stock News

CVAC - CureVac N.V.

03/28/23 4:25 PM

Nasdaq : CVAC

CureVac Announces Voting Results of Extraordinary General Meeting

CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's

RHEA-AI

neutral

02/10/23 4:20 PM

Nasdaq : CVAC

offering

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares

CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its follow-on public

RHEA-AI

neutral

02/07/23 2:20 AM

Nasdaq : CVAC

offering

CureVac Announces Proposed Public Offering of Common Shares

CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer $200 million of its

RHEA-AI

neutral

02/01/23 7:15 AM

Nasdaq : CVAC

CureVac Welcomes Myriam Mendila as New Chief Development Officer

CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on

RHEA-AI

neutral

01/31/23 9:35 AM

Nasdaq : CVAC

CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)

RHEA-AI

very positive

01/30/23 8:30 AM

Nasdaq : CVAC

covid-19

CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs

Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants in adults age ≥65 Flu: monovalent

RHEA-AI

neutral

01/09/23 7:15 AM

Nasdaq : CVAC

management

CureVac Appoints Alexander Zehnder as CEO From April 1, 2023

CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company

RHEA-AI

very positive

01/06/23 7:15 AM

Nasdaq : CVAC

covid-19

CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies All candidates use CureVac's advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low doses The

RHEA-AI

neutral

12/14/22 4:25 PM

Nasdaq : CVAC

CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program

CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Chief Executive Officer Franz-Werner Haas, Chief

RHEA-AI

neutral

11/16/22 7:30 AM

Nasdaq : CVAC

earnings

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update

Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023 Strengthening oncology position based on preparations for new clinical

RHEA-AI

positive

1 2 3 4 5 6 7 Next